Q-omics provides the consensus-scored RN7SL208P profile across patient tissues and cancer cell-line models. RN7SL208P expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RN7SL208P is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, RN7SL208P RNA expression shows 9,111 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, COAD, and LSCC as cancer lineages where RN7SL208P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RN7SL208P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RN7SL208P survival associations across molecular data types. RN7SL208P RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RN7SL208P RNA expression–survival associations across cancer types. High RN7SL208P expression shows unfavorable associations in MESO, HNSC, LUAD and SKCM, but favorable associations in READ and BLCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for RN7SL208P RNA expression.
This table summarizes RN7SL208P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RN7SL208P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RN7SL208P shows lower tumor expression in COAD and KICH and higher tumor expression in HNSC, KIRP, LUAD and UCEC. The COAD box plot shows higher RN7SL208P RNA expression in normal versus tumor tissue (log2 FC = −0.473, t-test p < 0.001).
This table shows molecular features associated with RN7SL208P in patient tissues and cancer cell lines. In patient samples, RN7SL208P shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
